LEADER 02721nam  2200613 a 450 
001 9910786222803321
005 20220106004854.0
010   $a1-118-68218-1
010   $a1-299-46883-7
010   $a1-118-68220-3
035   $a(CKB)2670000000342126
035   $a(EBL)1165087
035   $a(OCoLC)836400729
035   $a(SSID)ssj0000856518
035   $a(PQKBManifestationID)12382870
035   $a(PQKBTitleCode)TC0000856518
035   $a(PQKBWorkID)10807891
035   $a(PQKB)10565313
035   $a(MiAaPQ)EBC1165087
035   $a(Au-PeEL)EBL1165087
035   $a(CaPaEBR)ebr10684967
035   $a(CaONFJC)MIL478133
035   $a(EXLCZ)992670000000342126
100   $a20110124d2011      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aNew mechanisms in glucose control$b[electronic resource] /$fAnthony H. Barnett, Jenny Grice
210   $aChichester, West Sussex $cWiley-Blackwell$d2011
215   $a1 online resource (74 p.)
300   $aDescription based upon print version of record.
311   $a1-118-68219-X 
311   $a1-4443-3461-1 
320   $aIncludes bibliographical references and index.
327   $aEpidemiology and pathogenesis of type 2 diabetes -- Overview of current diabetes management -- The incretin system -- The incretin mimetics -- Dipeptidyl peptidase-4 inhibitors -- Sodium-glucose cotransporter-2 inhibitors -- Pipeline diabetes therapies -- Bariatric surgery for the treatment of type 2 diabetes -- Organization of diabetes care.
330   $aNew Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabete
606   $aType 2 diabetes
606   $aHypoglycemic agents
606   $aObesity$xSurgery
615  0$aType 2 diabetes.
615  0$aHypoglycemic agents.
615  0$aObesity$xSurgery.
676   $a616.4/624
700   $aBarnett$b A. H$g(Anthony H.),$f1951-$0855736
701   $aGrice$b Jenny$01541837
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910786222803321
996   $aNew mechanisms in glucose control$93794223
997   $aUNINA